Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-01-09 00:00:00 ET · period of report 2023-01-05 · accession 0001415889-23-000708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-09 | 2023-01-05 | JBIO | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
| D | 2023-01-09 | 2023-01-05 | JBIO | NIVEN RALPH | CSO | S - Sale+OE | $26.40 | -2,250 | 1,609 | -58% | -$59.4K |
| DM | 2023-01-09 | 2023-01-05 | JBIO | NIVEN RALPH | CSO | M - OptEx | $0.00 | -2,250 | 55.2K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-05 | M | A | 1,600 | $2.14 | 3,859 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-05 | M | A | 650 | $1.74 | 2,259 | D | — | — | |
| 3 | Common | Common Stock | 2023-01-05 | S | D | 2,250 | $26.40 | 1,609 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.21 to $26.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | M | D | 450 | $0.00 | 21,408 | D | $1.74 · — to 2030-09-03 | 450 Common Stock | (F3) A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | M | D | 200 | $0.00 | 13,288 | D | $1.74 · — to 2030-09-03 | 200 Common Stock | (F4) A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | M | D | 200 | $0.00 | 15,094 | D | $2.14 · — to 2031-04-01 | 200 Common Stock | (F5) A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | M | D | 650 | $0.00 | 46,008 | D | $2.14 · — to 2031-04-01 | 650 Common Stock | (F6) A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-01-05 | M | D | 750 | $0.00 | 55,232 | D | $2.14 · — to 2031-04-01 | 750 Common Stock | (F7) A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |